A B S T R A C T We have studied the influence of verapamil hydrochloride on the in vitro and in vivo effects of daunorubicin in Ehrlich ascites carcinoma. Daunorubicin-sensitive tumor was rendered resistant to daunorubicin by the continuous treatment of sequential generations of tumor-bearing BALB/c mice. The ability of daunorubicin to inhibit [3H]uridine and [3H]thymidine incorporation and the effect of daunorubicin on the mean survival time of host animals bearing daunorubicin-sensitive and daunorubicin-resistant Ehrlich ascites carcinoma were compared. The addition of verapamil to daunorubicin in vitro reduced the concentration of daunorubicin required to inhibit 50% of DNA and RNA synthesis in the daunorubicin-resistant tumor to that required in the daunorubicin-sensitive tumor, from 6 and 4.4 ,g/ml to 1.5 and 1.3 Ag/ ml, respectively. Verapamil also restored drug sensitivity to daunorubicin-resistant Ehrlich ascites carcinoma in vivo. The 21.7±0.7 d mean survival time (MST) of BALB/c mice bearing daunorubicin-resistant tumor treated with daunorubicin alone rose to 44.0±0.7 d when the same tumor was treated with verapamil and daunorubicin, P < 0.001. This in vivo effect is specific for daunorubicin-resistant Ehrlich ascites carcinoma, since there is no alteration in MST of BALB/c mice bearing daunorubicin-sensitive or daunorubicinresistant tumor when they are treated with verapamil alone or when BALB/c mice bearing daunorubicinsensitive tumor are treated with daunorubicin and verapamil.
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INTRODUCTION
Altered drug transport characterizes the resistance of experimental tumors to several classes of chemotherapeutic agents including the anthracycline antibiotics Received for publication 27 May 1982 and in revised form 4 August 1982. adriamycin and daunorubicin (1-3). Tsuruo et al. (4) recently reported that verapamil, the calcium influx inhibitor, enhanced the cellular level of vincristine in vincristine-sensitive P388 leukemia 2-fold, and in vincristine-resistant P388 leukemia 10-fold. Verapamil did not alter binding of vincristine to tubulin and it was felt that the enhanced accumulation of vincristine in these cell lines could be explained by the inhibition of vincristine efflux (4). Because anthracycline antibiotic resistance is also related to altered membrane transport by anthracycline-resistant tumor cells, (1-3) we have investigated the effect of verapamil on daunorubicin-resistant Ehrlich ascites carcinoma. 
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